{
    "nct_id": "NCT03631706",
    "official_title": "An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (Bintrafusp Alfa) Versus Pembrolizumab as a First-line Treatment in Patients With PD-L1 Expressing Advanced Non-small Cell Lung Cancer",
    "inclusion_criteria": "* Histologically confirmed diagnosis of advanced NSCLC\n* Have not received prior systemic therapy treatment for their advanced/Stage four NSCLC. Completion of treatment with cytotoxic chemotherapy, biological therapy, and/or radiation as part of neoadjuvant/adjuvant therapy is allowed as long as therapy was completed at least 6 months prior to the diagnosis of metastatic disease. Confirmation of resolution of toxic effects of previous neoadjuvant/adjuvant chemotherapy therapy to Grade less than or equal to 1. For radiation toxicity or prior major surgeries, participants should have recovered from side effects and/or complications\n* Have measurable disease based on RECIST 1.1\n* Have a life expectancy of at least 3 months\n* Availability of tumor tissue (less than 6 months old) before the first dose is mandatory to determine PD-L1 expression level prior to enrollment\n* PD-L1 high status as determined by central testing\n* Other protocol defined inclusion criteria could apply\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Participants with nonsquamous NSCLC histologies whose tumor harbors any of the following molecular alterations and targeted therapy is locally approved: epidermal growth factor receptor (EGFR) sensitizing (activating) mutation, anaplastic lymphoma kinase (ALK) translocation, ROS1 rearrangement, or BRAF V600E mutation\n* Has received major surgery within 4 weeks prior to the first dose of study intervention; received thoracic radiation therapy of greater than 30 units of gray (Gy) within 6 months prior to the first dose of study\n* Known severe hypersensitivity to investigational products (M7824 or pembrolizumab), or any components in their formulations\n* Previous malignant disease (other than the target malignancy to be investigated in this study) within the last 3 years\n* Other protocol defined exclusion criteria could apply",
    "miscellaneous_criteria": ""
}